OR WAIT 15 SECS
© 2020 MJH Life Sciences and Pharmaceutical Technology. All rights reserved.
© 2020 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
More complex and challenging compounds require a tailored formulation approach.
UK approves emergency use for Pfizer/BioNTech vaccine; industry ups manufacturing, awaits FDA EUA decisions.
December 04, 2020
Startup company Vivlion has signed a non-exclusive license agreement with ERS Genomics granting access to CRISPR/Cas9 patent portfolio.
New data from CGT Catapult has demonstrated progression by the industry toward commercialization of therapies and an increase in GMP manufacturing space.
Lonza has formed a long-term, strategic collaboration with a global biopharma company for bioconjugation.
December 03, 2020
Honeywell’s project team has remotely and efficiently migrated Richter Gedeon’s process control system with limited onsite staffing and resources.
A novel PTA technology captures more than 95% of the genomes of single cells, providing more uniform, accurate, and reproducible single-cell analysis data.
The collaboration addresses the need for risk mitigation plans in cell therapies.
Janssen announces rolling submissions for its COVID-19 vaccine with Health Canada and EMA.
The gene therapy increases the ability of retina cells to make a soluble form of CD59, a protein that shields the retina from damage, to prevent additional damage and to preserve vision.
Set to be operational by the first quarter of 2022, the 140,000-ft2 facility will feature up to six 2000-L, single-use bioreactor systems along with additional harvest and purification equipment to produce up to 100 commercial batches annually.
Under the terms of the partnership, Colorcon will work to accelerate i2O’s research and development efforts.